Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 8—August 2005

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A5

Relative risk (RR) and 95% confidence interval (95% CI) for influenza infection and protective efficacy of individual trials with estimate of preexposure (seasonal) prophylaxis

Trial Drug RR (95% CI) Protective efficacy (%) p value for heterogeneity
Hayden et al. (11) Oseltamivir 0.26 (0.13–0.50) 74
Monto et al. (15) Zanamivir 0.32 (0.17–0.63) 68
Overall 0.29 (0.20–0.43) 71 0.643

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.